KFS
Kelly Financial Services Portfolio holdings
AUM
$339M
1-Year Return
12.04%
This Quarter Return
-0.55%
1 Year Return
+12.04%
3 Year Return
+48.57%
5 Year Return
+68.33%
10 Year Return
–
AUM
$178M
AUM Growth
-$2.41B
(-93%)
Cap. Flow
-$27.7B
Cap. Flow
% of AUM
-15,613.81%
Top 10 Holdings %
Top 10 Hldgs %
74.86%
Holding
671
New
32
Increased
1
Reduced
611
Closed
24
Top Buys
| 1 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$60.2K |
| 2 |
Nektar Therapeutics
NKTR
|
$53.9K |
| 3 |
Vanguard Total Stock Market ETF
VTI
|
$48.3K |
| 4 |
INmune Bio
INMB
|
$38.8K |
| 5 |
DT Midstream
DTM
|
$27.4K |
Top Sells
| 1 |
iShares Core S&P 500 ETF
IVV
|
$7.27B |
| 2 |
iShares Expanded Tech Sector ETF
IGM
|
$4.71B |
| 3 |
iShares MSCI USA Min Vol Factor ETF
USMV
|
$2.01B |
| 4 |
iShares Core S&P Mid-Cap ETF
IJH
|
$1.82B |
| 5 |
iShares Core Dividend Growth ETF
DGRO
|
$1.45B |
Sector Composition
| 1 | Technology | 2.92% |
| 2 | Materials | 2.24% |
| 3 | Healthcare | 1.73% |
| 4 | Financials | 1.46% |
| 5 | Industrials | 1.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TTOO
551
DELISTED
T2 Biosystems, Inc
TTOO
| – | – |
0
| – | -$1.59M |
|
552
Karyopharm Therapeutics
KPTI
$58.4M
| $1.46K | ﹤0.01% |
17
-155
| -90% | -$13.3K |
|
553
Clearway Energy Class C
CWEN
$3.38B
| $1.42K | ﹤0.01% |
47
-1,181
| -96% | -$35.7K |
|
554
Kroger
KR
$44.9B
| $1.42K | ﹤0.01% |
35
-1,306
| -97% | -$52.8K |
|
555
Halliburton
HAL
$19.2B
| $1.39K | ﹤0.01% |
64
-1,421
| -96% | -$30.9K |
|
556
Teva Pharmaceuticals
TEVA
$21.2B
| $1.36K | ﹤0.01% |
140
-1,246
| -90% | -$12.1K |
|
|
557
Clearway Energy Class A
CWEN.A
$3.2B
| $1.34K | ﹤0.01% |
48
-1,137
| -96% | -$31.8K |
|
558
Ferrari
RACE
$88.2B
| $1.26K | ﹤0.01% |
6
-1,230
| -100% | -$257K |
|
559
Kontoor Brands
KTB
$4.47B
| $1.24K | ﹤0.01% |
25
-1,372
| -98% | -$68.1K |
|
560
Hexcel
HXL
$5.1B
| $1.22K | ﹤0.01% |
21
-1,262
| -98% | -$73.4K |
|
561
Ribbon Communications
RBBN
$737M
| $1.2K | ﹤0.01% |
200
-1,322
| -87% | -$7.91K |
|
|
TELL
562
DELISTED
Tellurian Inc.
TELL
| $1.17K | ﹤0.01% |
300
-1,095
| -78% | -$4.28K |
|
563
Ventas
VTR
$30.8B
| $1.14K | ﹤0.01% |
21
-1,153
| -98% | -$62.8K |
|
|
VIVS
564
VivoSim Labs, Inc. Common Stock
VIVS
$5.88M
| $1.14K | ﹤0.01% |
14
-118
| -89% | -$9.63K |
|
565
Occidental Petroleum
OXY
$45.9B
| $1.09K | ﹤0.01% |
37
-1,120
| -97% | -$33.1K |
|
566
Unilever
UL
$159B
| $1.08K | ﹤0.01% |
20
-1,139
| -98% | -$61.7K |
|
567
Gilead Sciences
GILD
$140B
| $1.04K | ﹤0.01% |
15
-1,150
| -99% | -$79.9K |
|
568
Acushnet Holdings
GOLF
$4.47B
| $1.04K | ﹤0.01% |
22
-1,073
| -98% | -$50.6K |
|
569
Schwab Fundamental US Large Company Index ETF
FNDX
$19.9B
| $1.02K | ﹤0.01% |
57
-3,045
| -98% | -$54.7K |
|
570
Baxter International
BAX
$12.1B
| $1.01K | ﹤0.01% |
13
-995
| -99% | -$77.4K |
|
571
Ionis Pharmaceuticals
IONS
$9.46B
| $1.01K | ﹤0.01% |
30
-1,167
| -97% | -$39.1K |
|
572
Iterum Therapeutics
ITRM
$28.2M
| $1.01K | ﹤0.01% |
120
-157
| -57% | -$1.32K |
|
573
Schwab Intermediately-Term US Treasury ETF
SCHR
$11.5B
| $935 | ﹤0.01% |
32
-1,840
| -98% | -$53.8K |
|
574
Real Estate Select Sector SPDR Fund
XLRE
$7.58B
| $845 | ﹤0.01% |
19
-823
| -98% | -$36.6K |
|
575
PharmaCyte Biotech
PMCB
$6.41M
| $831 | ﹤0.01% |
+262
| New | +$831 |
|